Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
J Neurol Sci ; 285(1-2): 246-9, 2009 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-19616221

RESUMEN

We report a patient with Parkinson's disease whose whole body drenching sweats were completely alleviated by stimulation of the subthalamic nucleus and/or adjacent structures. Sweating reappeared 4h after the pulse generator (stimulation) was turned off and ceased when stimulation was resumed. Imaging studies with reconstruction indicated that stimulation of, or spread of stimulation from, the caudal medial aspect of the right subthalamic nucleus and/or the caudal aspect of the ventral thalamus/zona incerta may be responsible for alleviating the drenching sweats.


Asunto(s)
Estimulación Encefálica Profunda , Enfermedad de Parkinson/fisiopatología , Enfermedad de Parkinson/terapia , Núcleo Subtalámico/fisiopatología , Sudoración/fisiología , Humanos , Imagen por Resonancia Magnética , Masculino , Persona de Mediana Edad , Trastornos del Movimiento/fisiopatología , Trastornos del Movimiento/cirugía , Trastornos del Movimiento/terapia , Enfermedad de Parkinson/cirugía , Núcleo Subtalámico/patología , Tálamo/patología , Tálamo/fisiopatología , Factores de Tiempo , Resultado del Tratamiento
2.
Cancer Immunol Immunother ; 48(9): 533-9, 1999 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-10602891

RESUMEN

Levamisole (LMS), utilized in the adjuvant treatment of patients with stage III colon cancer, is immunomodulatory. To determine whether alterations in immune parameters before, during and after 12 months of 5FU/LMS therapy correlate with disease-free survival, 38 patients enrolled on Southwest Oncology Group (SWOG) protocol 8899 received extensive lymphocyte phenotypic analysis prior to therapy and 3, 6, 12 and 15 months after treatment initiation. The median follow-up of patients is 41 months. Significant increases in the proportion and total number of CD56+ natural killer cells were seen, starting at 3 months and continuing until 15 months (P < 0. 001). Increases in the total numbers of cells expressing CD25 (interleukin-2 receptor), VLA4 and the combinations of CD4: CD45RA and CD4:CDw29 were not evident during therapy but were seen at 15 months (P < 0.05: CD25, CD4:CDw29, CD4:CD45RA; P < 0.001: VLA4). Low levels of CD8+ cells prior to treatment initiation and after 3 months of therapy correlated with early relapse within the first year of 5FU/LMS treatment. Patients who have remained disease-free (n = 22, median follow-up 45 months) demonstrated increases in the total numbers of CD8+, CD25+, CD56+, VLA4+, CD4: CDw29 and CD4:CD45RA cells, primarily at 15 months. In contrast, patients who relapsed had decreased numbers of CD8+, CD4:CDw29, CD4: CD45RA and VLA4+ cells and minimal increases in CD56+ and CD25+ cells. Statistically significant differences between the late-relapse group and the group remaining disease-free were seen for CD25+, CD4: CD45RA and CD4:CDw29 cells at the 15-month assay time (P = 0.0276, P = 0.0349, P = 0.0178 respectively). In conclusion, multiple alterations in lymphocyte phenotype, with increases in the proportion and total number of cells involved in cell-mediated immune responses, were seen during and especially following completion of therapy with 5FU/LMS. Many of these changes are significantly associated with clinical outcome and may be useful for risk stratification of stage III colon cancer patients following completion of adjuvant therapy.


Asunto(s)
Adyuvantes Inmunológicos/uso terapéutico , Antimetabolitos Antineoplásicos/uso terapéutico , Neoplasias del Colon/inmunología , Fluorouracilo/uso terapéutico , Levamisol/uso terapéutico , Neoplasias del Colon/tratamiento farmacológico , Neoplasias del Colon/mortalidad , Neoplasias del Colon/patología , Neoplasias del Colon/terapia , Terapia Combinada , Supervivencia sin Enfermedad , Humanos , Inmunofenotipificación , Tablas de Vida , Estadificación de Neoplasias , Análisis de Supervivencia , Resultado del Tratamiento
3.
Am J Surg ; 177(4): 307-10, 1999 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10326849

RESUMEN

BACKGROUND: Epidemiological studies have suggested that soluble dietary fibers are hypocholesterolemic and may inhibit cholelithiasis. METHODS: Thirty prairie dogs were placed on a cholesterol-supplemented lithogenic diet. Ten animals received 5% psyllium (PSY) and 10 animals received 5% cellulose. After 6 weeks all gallbladders were inspected for stones; blood and bile were collected for analysis. RESULTS: Cholesterol stones were present in 8 of 10 of the control animals, in 6 of 10 of the cellulose group, and 3 of 10 of the PSY animals (P <0.05). Concentrations of cholesterol and chenodeoxycholic acid (CDCA) were significantly lower in the PSY group compared with controls (0.49 versus 0.88 mM and 4.2 versus 9.2 mM, respectively) leading to a significant reduction in the cholesterol saturation index (0.62 versus 1.2). CONCLUSIONS: A dietary soluble fiber (PSY) inhibits cholesterol stone formation by reducing the biliary cholesterol saturation index. This protective effect is associated with a selective decrease in biliary cholesterol and CDCA.


Asunto(s)
Catárticos/metabolismo , Colelitiasis/prevención & control , Colesterol/metabolismo , Fibras de la Dieta , Psyllium/metabolismo , Animales , Catárticos/administración & dosificación , Colelitiasis/fisiopatología , Colelitiasis/veterinaria , Masculino , Psyllium/administración & dosificación , Sciuridae
4.
Cancer Immunol Immunother ; 38(6): 394-8, 1994 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-7515770

RESUMEN

Levamisole (LMS) and 5-fluorouracil (5FU) administered adjuvantly are effective in reducing the relapse rate following surgical resection of Duke's stage C colon carcinoma. It has been postulated that LMS acts to stimulate the immune system and that this is one mechanism through which this drug exerts its antitumor effects. In this study, peripheral blood mononuclear cells (PBMC) were analyzed in nine patients with surgically resected colon carcinoma prior to initiation of adjuvant LMS/5FU and at several subsequent times while patients were on therapy. Changes in lymphocyte phenotype and soluble interleukin-2 receptor (sIL-2R) between pre-study samples and samples obtained during adjuvant LMS/5FU were evaluated. Significant increases were seen in the proportion of PBMC expressing natural killer (NK) antigen CD56 (14.7 +/- 2.4% versus 18.1 +/- 2.6%; P < 0.05) and surface IL-2R (CD25; 0% versus 0.42 +/- 0.15%; P < 0.05), in sIL-2R (314 +/- 86 U/ml versus 736 +/- 173 U/ml; P < 0.05), and in the CD4:CD8 ratio (2.34 +/- 0.93 versus 3.47 +/- 1.23; P < 0.01). A significant decrease in the proportion of CD8+ PBMC (24.7 +/- 3.8% versus 18.8 +/- 2.6%; P < 0.01) and total CD8+ PBMC (537 +/- 118 versus 324 +/- 37; P < 0.01) was seen. The increase in CD56+ cells correlated with sIL2R levels (r = 0.46; P < 0.05). No changes were noted for CD3, CD4, CD5, CD14, CD16, CD19, CDw49a, or TCR delta. The greatest increase in CD56+ cells and the smallest reduction in CD8+ cells were seen in the subgroup of patients who remained disease-free following adjuvant chemotherapy. This study suggests that adjuvant LMS/5FU has significant stimulatory effects on the immune system, which correlate with patient outcome and may account at least in part for its clinical efficacy.


Asunto(s)
Fluorouracilo/farmacología , Levamisol/farmacología , Linfocitos/efectos de los fármacos , Antígenos CD/análisis , Antígenos de Diferenciación de Linfocitos T/análisis , Antígeno CD56 , Quimioterapia Adyuvante , Neoplasias del Colon/sangre , Neoplasias del Colon/tratamiento farmacológico , Neoplasias del Colon/cirugía , Humanos , Células Asesinas Naturales/efectos de los fármacos , Células Asesinas Naturales/inmunología , Linfocitos/inmunología , Fenotipo , Receptores de Interleucina-2/análisis
5.
J Trauma ; 35(2): 303-9; discussion 309-11, 1993 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-8355313

RESUMEN

Combination therapy for nosocomial pneumonia with a beta-lactam and aminoglycoside is widely accepted because of synergy and reduction of resistant bacteria. This prospective study of 109 trauma patients (94 blunt, 15 penetrating) with nosocomial pneumonia was performed in consecutive phases. In phase 1, patients were randomized to an anti-pseudomonal third-generation cephalosporin--cefoperazone or ceftazidime. Gentamicin was added to each regimen in phase 2. The mean age of the patients was 37 years, the mean ISS was 31, and there were no differences among the four treatment groups relative to associated injuries. Patients receiving monotherapy had a 56% cure rate compared with 31% for combination therapy (p < 0.04). Persistence rates were similar in these two groups (15% and 20%), but superinfection was significantly higher in the combination group (49% vs. 28%; p < 0.04). The predominant superinfecting organism was methicillin-resistant Staphylococcus aureus (MRSA). Nine patients died (5% monotherapy, 10% combination), and eight had a superinfection. We conclude that monotherapy had a higher cure rate than combination therapy for empiric therapy of pneumonia in our trauma patients. Combination therapy failed because of superinfection (primarily MRSA). Emergence of MRSA may be from host overgrowth or plasmid-mediated induction of resistance, possibly caused by gentamicin.


Asunto(s)
Cefoperazona/uso terapéutico , Ceftazidima/uso terapéutico , Infección Hospitalaria/tratamiento farmacológico , Gentamicinas/uso terapéutico , Neumonía/tratamiento farmacológico , Infecciones Estafilocócicas/tratamiento farmacológico , Sobreinfección/tratamiento farmacológico , Heridas no Penetrantes/complicaciones , Heridas Penetrantes/complicaciones , Adolescente , Adulto , Anciano , Cefoperazona/administración & dosificación , Ceftazidima/administración & dosificación , Infección Hospitalaria/epidemiología , Infección Hospitalaria/etiología , Infección Hospitalaria/microbiología , Quimioterapia Combinada , Femenino , Gentamicinas/administración & dosificación , Mortalidad Hospitalaria , Humanos , Incidencia , Infusiones Intravenosas , Puntaje de Gravedad del Traumatismo , Masculino , Resistencia a la Meticilina , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Neumonía/epidemiología , Neumonía/etiología , Neumonía/microbiología , Estudios Prospectivos , Infecciones Estafilocócicas/epidemiología , Infecciones Estafilocócicas/etiología , Infecciones Estafilocócicas/microbiología , Sobreinfección/epidemiología , Sobreinfección/etiología , Sobreinfección/microbiología
6.
Am J Surg ; 161(4): 470-4, 1991 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-2035766

RESUMEN

Dietary ethanol has been reported to protect against cholesterol gallstone formation. Because enhanced gallbladder absorption of water is important in cholesterol cholelithiasis, we examined the hypothesis that ethanol acts by inhibiting the absorptive function of the gallbladder. Eighteen adult male prairie dogs were fed a lithogenic liquid diet containing 0.4% cholesterol. Half of the animals received 30% of total calories as ethanol, whereas their pair-fed controls received equicaloric amounts of maltose-dextrin. After 3 months, the gallbladders were inspected for gallstones and crystals, and gallbladder and hepatic bile were analyzed. Cholesterol stones and crystals were present in all nine controls. None of the alcohol-fed animals had stones, but four had cholesterol crystals. Gallbladder cholesterol, phospholipids, and total calcium were significantly decreased in alcohol-fed animals. In both gallbladder and hepatic bile, the cholesterol saturation index was significantly lower in alcohol-fed animals, as was the ratio of trihydroxy to dihydroxy bile salts. The ethanol-supplemented diet produced a significant decrease in the absorption of water by the gallbladder as indicated by changes in the gallbladder bile to hepatic bile ratios of the total bile salt concentration (7.29 +/- 1.25 versus 3.84 +/- 0.56; p less than 0.05) and the total calcium (3.37 +/- 0.24 versus 2.43 +/- 0.29; p less than 0.05). These findings indicate that the protective effect of ethanol may be related to its ability both to inhibit gallbladder absorption of water and to alter the composition of biliary lipids.


Asunto(s)
Colelitiasis/prevención & control , Colesterol/farmacocinética , Etanol/farmacología , Vesícula Biliar/efectos de los fármacos , Absorción , Animales , Bilis/química , Ácidos y Sales Biliares/análisis , Calcio/análisis , Colelitiasis/fisiopatología , Colesterol/análisis , Colesterol/sangre , Colesterol en la Dieta , Cromatografía Líquida de Alta Presión , Dieta , Etanol/administración & dosificación , Vesícula Biliar/metabolismo , Masculino , Fosfolípidos/análisis , Sciuridae , Agua/análisis , Agua/metabolismo
7.
Ann Surg ; 195(3): 305-13, 1982 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-6800314

RESUMEN

Lead intoxication (plumbism) from retained bullets has rarely been reported but may be fatal if unrecognized. Bullets lodged within joint spaces or pseudocysts are more likely to develop this complication, although patients with retained missiles in other locations may also be at risk. Subtle findings such as the occurrence of unexplained anemia, abdominal colic, nephropathy, or neurologic deterioration in patients with retained missiles may suggest consideration of plumbism. An intercurrent metabolic stress such as infection, endocrinopathy, or alcoholism may be a precipitating factor. Among the various diagnostic studies available, mass spectrometric stable isotope dilution analysis may be the most reliable. It is important to employ chelation therapy prior to any operative intervention. This will reduce the mobilization of lead from bone during or following the surgical procedure.


Asunto(s)
Intoxicación por Plomo/etiología , Heridas por Arma de Fuego/complicaciones , Adulto , Quistes/cirugía , Dimercaprol/uso terapéutico , Ácido Edético/uso terapéutico , Femenino , Humanos , Disco Intervertebral/cirugía , Intoxicación por Plomo/diagnóstico , Intoxicación por Plomo/tratamiento farmacológico , Masculino , Espectrometría de Masas , Persona de Mediana Edad , Cirugía Torácica , Factores de Tiempo , Heridas por Arma de Fuego/cirugía
8.
J Clin Psychiatry ; 43(2): 70-2, 1982 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-7056707

RESUMEN

A 15 year old boy was evaluated in the psychiatric emergency room for the acute onset of "confusion,"insomnia, headache, and shaking of one week's duration. Two days later hallucinations, formication and a movement disorder emerged characterized by action tremor, myoclonus, chorea and ataxia. Further history revealed inhalation of gasoline for its euphoric effects. Plasma lead levels were in the toxic range. Chelation therapy reversed the clinical symptoms. Behavioral changes and a movement disorder in the context of gasoline inhalation are highly suggestive of organic lead encephalopathy. Recognition of this syndrome is important as chelation therapy is effective.


Asunto(s)
Gasolina , Intoxicación por Plomo/psicología , Trastornos del Movimiento/inducido químicamente , Petróleo , Trastornos Relacionados con Sustancias/psicología , Adolescente , Gasolina/efectos adversos , Alucinaciones/inducido químicamente , Alucinaciones/psicología , Humanos , Discapacidad Intelectual/inducido químicamente , Discapacidad Intelectual/psicología , Masculino , Trastornos del Movimiento/psicología , Petróleo/efectos adversos
10.
Compr Ther ; 7(4): 38-44, 1981 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-7237986

RESUMEN

Parkinsonism is a movement disorder related to a central nervous system dopamine deficiency. L-dopa with or without carbidopa is presently the most effective medication. The use of this drug should be delayed as long as possible, and overtreatment should be avoided. Complications of long-term parkinsonism may respond in part to the direct dopamine receptor agonists. Physical therapy and emotional support for the patients and their families are an integral part of the management of the patient with Parkinson's disease.


Asunto(s)
Enfermedad de Parkinson/tratamiento farmacológico , Acetilcolina/antagonistas & inhibidores , Acetilcolina/fisiología , Amantadina/uso terapéutico , Apomorfina/análogos & derivados , Apomorfina/farmacología , Bromocriptina/farmacología , Carbidopa/efectos adversos , Carbidopa/uso terapéutico , Consejo , Dopamina/fisiología , Humanos , Levodopa/efectos adversos , Levodopa/uso terapéutico , Inhibidores de la Monoaminooxidasa , Manifestaciones Neurológicas , Enfermedad de Parkinson/terapia , Modalidades de Fisioterapia , Receptores Dopaminérgicos/efectos de los fármacos , Tálamo/cirugía
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA